Physician
Oncology
Dr. Charles F. Lemaistre, MD
|
|
Give Review
Charles F. Lemaistre, MD is an expert in the field of Oncology. He went to University of Texas Southwestern Medical School. Charles Lemaistre is also a published doctor. He has 29 paper published. The most recent paper is: Indications for Autologous and Allogeneic Hematopoietic CellTransplantation: Guidelines from the American Society forBlood and Marrow Transplantation.
Publications
- Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation.
- Guidelines for Defining and Implementing Standard Episode of Care for Hematopoietic Stem Cell Transplantation within the Context of Clinical Trials.
- Hospital Length of Stay in the First 100Â Days after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia in Remission: Comparison among Alternative Graft S...
- Survival improvements in adolescents and young adults after myeloablative allogeneic transplantation for Acute lymphoblastic leukemia.
- Trends in use of and survival after autologous hematopoietic cell transplantation in North America, 1995-2005: significant improvement in survival for Lymphoma and mye...
- Significant Improvement in Survival After Allogeneic Hematopoietic Cell Transplantation During a Period of Significantly Increased Use, Older Recipient Age, and Use of...
- High white blood cell concentration in the peripheral blood stem cell product can induce seizures during infusion of autologous peripheral blood stem cells.
- Relationship of race/ethnicity and survival after single umbilical cord blood transplantation for adults and children with Leukemia and myelodysplastic syndromes.
- Abandonment of high-dose chemotherapy/hematopoietic cell transplants for breast cancer following negative trial results.
- Outcomes of hematologic malignancies after unrelated donor hematopoietic cell transplantation according to place of residence.
- Race and outcomes of autologous hematopoietic cell transplantation for multiple Myeloma.
- Allogeneic transplants in follicular lymphoma: higher risk of Disease progression after reduced-intensity compared to myeloablative conditioning.
- Granulocyte colony-stimulating factor mobilizes more dendritic cell subsets than granulocyte-macrophage colony-stimulating factor with no polarization of dendritic cel...
- Association of transplant center and physician factors on mortality after hematopoietic stem cell transplantation in the United States.
- Autologous transplantation for diffuse aggressive non-Hodgkin Lymphoma in first relapse or second remission.
- Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer.
- Defining Medicare coverage for MDS treatment and research: a time for action?
- Liver transplantation for sinusoidal obstructive syndrome (veno-occlusive Disease): case report with review of the literature and the UNOS database.
- Palifermin for oral mucositis after intensive therapy for hematologic cancers.
- The new apheresis and blood and marrow transplantation-related current procedural terminology codes for payment of apheresis and blood and marrow transplantation servi...
- What is quality in a transplant program?
- Impending challenges in the hematopoietic stem cell transplantation physician workforce.
- Influence of age and histology on outcome in adult non-Hodgkin Lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): a report from the Cen...
- Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic ste...
- High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis.
- High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot st...
- Phase I and pharmacokinetic study of once-daily dosing of intravenously administered busulfan in the setting of a reduced-intensity preparative regimen and allogeneic ...
- Allogeneic transplant physician and center capacity in the United States.
Schools
University of Texas Southwestern Medical Center At Dallas
Sw Med Center
Ut Health Science Center
Procedures Preformed
- Bone Marrow Transplant
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Anemia
- Chronic Myeloid Leukemia (CML)
- Coagulation Disorders (incl. Hemophilia)
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna
- Amerigroup (Wellpoint)
- Blue Cross Blue Shield
- Great West Healthcare-Cigna PPO
- Commercial Insurance Company
- Coventry Health Care
- Golden Rule
- Choice Care PPO
- Preferred PPO
- Medicaid
- Medicare MCR
- Molina
- MultiPlan PPO
- PHCS Network PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Education
-
University of Texas Health Science Center -
University of Texas Southwestern Medical School
Helpful Reviews
Similar Doctors
|
|
Dr. Lindsay L. Peterson, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Irene Kazhdan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lon S. Smith, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert A. Marciniak, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Allison M. Garner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amita Patnaik, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Monica M. Mita, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Jayasree N. Rao, MD
This Doctor is OpenDoctor Recommended.
|